← All trials
NCT04451863
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Sep 30, 2023
- Completion date
- Sep 30, 2024
- First posted
- Jun 30, 2020
- Last posted
- Jun 30, 2020
- Enrollment
- 45
- Arms / groups
- 15 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, Los AngelesLead sponsor
- National Center for Complementary and Integrative Health (NCCIH)Collaborator
- University of California, Los AngelesOfficial
- University of California, Los AngelesSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.